公开(公告)号：EP2203430A1

公开(公告)日：2010-07-07

申请号：EP08831558.5

申请日：2008-09-17

Applicant: Abbott Laboratories

Inventor： DONNER, Pamela L. ,  RANDOLPH, John T. ,  KRUEGER, Allan C. ,  BETEBENNER, David A. ,  HUTCHINSON, Douglas K. ,  LIU, Dachun ,  LIU, Yaya ,  LONGENECKER, Kenton L. ,  MARING, Clarence J. ,  PRATT, John K. ,  ROCKWAY, Todd W. ,  STEWART, Kent D. ,  WAGNER, Rolf ,  BARNES, David M. ,  CHEN, Shuang ,  FRANCZYK II, Thaddeus S. ,  GAO, Yi ,  HAIGHT, Anthony R. ,  HENGEVELD, John E. ,  HENRY, Rodger F. ,  KOTECKI, Brian J. ,  LOU, Xiaochun ,  ZHANG, Geoff G. Z.

IPC: C07D239/22 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D239/553 ,  A61K31/513 ,  A61K31/506 ,  A61P31/14

CPC classification number: C07D239/22 ,  A61K31/513 ,  C07D239/54 ,  C07D239/553 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10

Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. The compounds are usefull in the treatment of hepatitis C and are of the following general structure: Formula (I)

公开(公告)号：EP2051984A1

公开(公告)日：2009-04-29

申请号：EP07799771.6

申请日：2007-07-24

Applicant: ABBOTT LABORATORIES

Inventor： VISWANATH, Shekhar ,  BARTELT, Larry ,  LEANNA, Robert ,  RASMUSSEN, Michael ,  DHAON, Madhup ,  HENRY, Rodger ,  BORCHARDT, Thomas ,  CHEN, Shuang ,  ZHANG, Geoff

IPC: C07D498/18 ,  A61K31/395 ,  A61P37/06 ,  A61K31/4353

CPC classification number: C07D498/18

Abstract: A rapamycin analog composition includes a crystalline form of a rapamycin analog. The crystal can be a hydrate, dehydrate, solvate, or desolvate. The rapamycin analog can have a structure of Formula (I), which is optionally a prodrug, salt, derivative, or combination thereof: Formula (I)

Abstract translation: 雷帕霉素类似物组合物包括雷帕霉素类似物的结晶形式。 晶体可以是水合物，脱水物，溶剂化物或去溶剂化物。 雷帕霉素类似物可具有式（I）的结构，其任选为前药，盐，衍生物或其组合：式（I）

公开(公告)号：EP2099795A2

公开(公告)日：2009-09-16

申请号：EP07863920.0

申请日：2007-11-06

Applicant: ABBOTT LABORATORIES

Inventor： SCHRIMPF, Michael R ,  NERSESIAN, Diana L ,  SIPPY, Kevin B ,  JI, Jianguo ,  LI, Tao ,  SCANIO, Marc ,  SHI, Lei ,  LEE, Chih-hung ,  BUNNELLE, Willaim H ,  ZHANG, Geoff G.Z. ,  BRACKEMEYER, Paul J ,  CHEN, Shuang ,  HENRY, Rodger F

IPC: C07D451/14 ,  A61K31/395

CPC classification number: C07D471/18 ,  A61K31/095 ,  A61K31/439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07C309/29 ,  C07D451/14 ,  C07D471/08 ,  C07F5/022

Abstract: The invention relates to compounds that are azaadamantane derivatives of formula (I), particularly ether- or amine -substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

公开(公告)号：EP2203431A1

公开(公告)日：2010-07-07

申请号：EP08832330.8

申请日：2008-09-17

Applicant: Abbott Laboratories

Inventor： FLENTGE, Charles, A. ,  HUTCHINSON, Douglas, K. ,  BETEBENNER, David, A. ,  DEGOEY, David, A. ,  DONNER, Pamela, L. ,  KATI, Warren, M. ,  KRUEGER, Allan, C. ,  LIU, Dachun ,  LIU, Yaya ,  LONGENECKER, Kenton, L. ,  MARING, Clarence, J. ,  MOTTER, Christopher, E. ,  PRATT, John, K. ,  RANDOLPH, John, T. ,  ROCKWAY, Todd, W. ,  STEWART, Kent, D. ,  WAGNER, Rolf ,  BARNES, David, M. ,  CHEN, Shuang ,  FRANCZYK, Thaddeus, S., II ,  GAO, Yi ,  HAIGHT, Anthony, R. ,  HENGEVELD, John, E. ,  KOTECKI, Brian, J. ,  LOU, Xiaochun ,  ZHANG, Geoff, G., Z.

IPC: C07D239/22 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  A61K31/513 ,  A61P31/12

CPC classification number: C07D239/54 ,  A61K31/513 ,  A61K45/06 ,  C07D239/22 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  A61K2300/00

Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.